Literature DB >> 408154

Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin.

Y Bergman, J Haimovich.   

Abstract

A carcinogen-induced lymphoid tumor, denoted 38C-13, obtained in a T cell-depleted mouse of C3H/eB strain, was adapted to continuous culture in vitro and characterized with respect to its cell surface components. The cells possess IgM class immunoglobulins on their surface but do not secrete it. This membrane IgM is composed of mu and L-chains that are similar in apparent molecular weight to those of an IgM myeloma protein. It is also homogeneous as revealed by isoelectric focusing. The cells possess Fc receptors but lack complement receptors as well as Thy-1 and Ia alloantigens. These characteristics indicate that 38C-13 cells are transformed counterparts of small B lymphocytes at an early stage of differentiation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408154     DOI: 10.1002/eji.1830070702

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

1.  Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.

Authors:  Gregory Kanter; Junhao Yang; Alexei Voloshin; Shoshana Levy; James R Swartz; Ronald Levy
Journal:  Blood       Date:  2006-12-12       Impact factor: 22.113

2.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.

Authors:  A A McCormick; M H Kumagai; K Hanley; T H Turpen; I Hakim; L K Grill; D Tusé; S Levy; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Possible target of Abelson virus phosphokinase in cell transformation.

Authors:  G Pantelias; H M Jäck; M Wabl
Journal:  Experientia       Date:  1986-09-15

4.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

5.  Induction of amplified synthesis and secretion of IgM by fusion of murine 'b lymphoma with myeloma cells.

Authors:  R Laskov; K J Kim; R Asofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

6.  Lipopolysaccharide-induced transcription of the kappa immunoglobulin locus occurs on both alleles and is independent of methylation status.

Authors:  K J Nelson; E L Mather; R P Perry
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

7.  ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Authors:  Tove Olafsen; Shannon J Sirk; David J Betting; Vania E Kenanova; Karl B Bauer; Waldemar Ladno; Andrew A Raubitschek; John M Timmerman; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2010-01-06       Impact factor: 1.650

8.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

9.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Authors:  Tove Olafsen; David Betting; Vania E Kenanova; Felix B Salazar; Pat Clarke; Jonathan Said; Andrew A Raubitschek; John M Timmerman; Anna M Wu
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.